An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Inclusion Criteria

• •1. Subjects who have completed the PSMA ADC 2301 study and who, in the opinion of the investigator, are likely to benefit from continued treatment with PSMA ADC
• •2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• •3. If chemically castrated, subjects must agree to stay on androgen-deprivation therapy for the duration of the study
• •4. If applicable, men must agree to commit to the use of a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 30 days after the last dose of study drug